JPRN-UMIN000047044
Not yet recruiting
未知
sefulness of postoperative adjuvant chemotherapy in patients with colorectal cancer T1/T2, N(+) - Usefulness of postoperative adjuvant chemotherapy in patients with colorectal cancer T1/T2, N(+)
Japanese Foundation for Multidisciplinary Treatment of Cancer0 sites621 target enrollmentMarch 1, 2022
Conditionscolon cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- colon cancer
- Sponsor
- Japanese Foundation for Multidisciplinary Treatment of Cancer
- Enrollment
- 621
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Safety and efficacy of postoperative adjuvant chemotherapy with L-OHP base regimen followed by UFT plus LV for resectable liver metastases from colorectal cancerresectable liver metastases from colorectal cancerJPRN-UMIN000020631Kyoto University50
Completed
Not Applicable
OFT trialColorectal liver metastasisCRLM, FOLFOXJPRN-jRCT1051190106Hatano Etsuro50
Active, not recruiting
Phase 1
Chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastasesThe CHARISMA randomized multicenter clinical trialEUCTR2013-004952-39-NLErasmus MC Cancer Institute224
Completed
Phase 3
eo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases ;The CHARISMA randomized multicenter clinical trialLiver metastases colorectal cancer1001981510017998NL-OMON44796Erasmus MC, Universitair Medisch Centrum Rotterdam224
Not yet recruiting
Not Applicable
Chemotherapy followed by versus surgery alone in high-risk patients with colorectal liver metastasesColorectal liver metastases, clinical risk score, high risk patients, colorectale levermetastasen, klinische risico score, hoog risico patientenNL-OMON27498Prof. Dr. C. VerhoefErasmus MC Cancer Institute224